ALTA MANESS: Open Payments
NPI 1639514649 · HACKENSACK, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$39,104 in 171 payments from 9 companies in 2025. Trend: 2023 $21,895 · 2024 $13,398 · 2025 $39,104
Speaker / faculty: $25,784Consulting: $6,110Food & beverage: $3,590Travel & lodging: $3,508Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 50 | $18,924 |
| E.R. Squibb & Sons, L.L.C. | 40 | $12,955 |
| Janssen Pharmaceuticals, Inc | 10 | $6,470 |
| Alkermes, Inc. | 15 | $309 |
| Neurocrine BioSciences, Inc. | 48 | $301 |
| Otsuka America Pharmaceutical, Inc. | 4 | $79 |
| Lundbeck LLC | 2 | $31 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| Almatica Pharma LLC | 1 | $14 |
Products named: AUSTEDO XR, UZEDY, COBENFY, INVEGA SUSTENNA, ARISTADA, INGREZZA, INVEGA, REXULTI.
Industry payments across NJ — which companies pay providers there.
